- Home
- IMUX vs INVE Comparison
IMUX vs INVE Comparison
Compare IMUX & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- INVE
- Stock Information
- Founded
- IMUX 2016
- INVE 1990
- Country
- IMUX United States
- INVE United States
- Employees
- IMUX N/A
- INVE N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- INVE Computer peripheral equipment
- Sector
- IMUX Health Care
- INVE Technology
- Exchange
- IMUX Nasdaq
- INVE Nasdaq
- Market Cap
- IMUX 67.8M
- INVE 74.2M
- IPO Year
- IMUX N/A
- INVE 1997
- Fundamental
- Price
- IMUX $0.69
- INVE $3.11
- Analyst Decision
- IMUX Strong Buy
- INVE Strong Buy
- Analyst Count
- IMUX 6
- INVE 3
- Target Price
- IMUX $11.60
- INVE $6.50
- AVG Volume (30 Days)
- IMUX 2.6M
- INVE 62.8K
- Earning Date
- IMUX 08-07-2025
- INVE 08-07-2025
- Dividend Yield
- IMUX N/A
- INVE N/A
- EPS Growth
- IMUX N/A
- INVE N/A
- EPS
- IMUX N/A
- INVE 3.12
- Revenue
- IMUX N/A
- INVE $25,239,000.00
- Revenue This Year
- IMUX N/A
- INVE N/A
- Revenue Next Year
- IMUX N/A
- INVE $9.00
- P/E Ratio
- IMUX N/A
- INVE $0.99
- Revenue Growth
- IMUX N/A
- INVE N/A
- 52 Week Low
- IMUX $0.56
- INVE $2.86
- 52 Week High
- IMUX $2.11
- INVE $4.35
- Technical
- Relative Strength Index (RSI)
- IMUX 34.49
- INVE 50.83
- Support Level
- IMUX $0.68
- INVE $3.08
- Resistance Level
- IMUX $0.75
- INVE $3.28
- Average True Range (ATR)
- IMUX 0.06
- INVE 0.12
- MACD
- IMUX -0.00
- INVE 0.01
- Stochastic Oscillator
- IMUX 6.01
- INVE 53.70
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.